Pharmaceutical Technology

NOVEMBER 14, 2023

The company intends to use the funds to advance its cancer vaccine clinical pipeline, including a colorectal cancer vaccine.

52

52

World of DTC Marketing

JANUARY 4, 2022

after they were diagnosed with metastatic colon cancer. According to the study “financial hardship or “financial toxicity” is an increasingly recognized consequence of cancer treatment that results from high out-of-pocket medical costs (e.g., National costs for cancer care were estimated to be $190.2

Insurance 273

Insurance Transportation Medical Prescription 273

Pharmaceutical Technology

DECEMBER 20, 2023

PDS-01ADC is under clinical development by PDS Biotechnology and currently in Phase II for Colorectal Cancer.

52

52

Pharmacy Times

JUNE 12, 2023

Additionally, data from the SCARLET trial presented at ASCO 2023 indicate the safety and efficacy of sotorasib in combination with platinum-based chemotherapy treating non¬–small cell lung cancer.

Safety 49

Safety 49

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Colorectal Cancer.

40

40

Pharmaceutical Technology

JANUARY 8, 2024

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

JANUARY 8, 2024

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

FEBRUARY 8, 2024

INCB-161734 is under clinical development by Incyte and currently in Phase I for Colorectal Cancer.

40

40

Pharmaceutical Technology

DECEMBER 24, 2023

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Metastatic Colorectal Cancer.

Biopharma 40

Biopharma 40

Pharmaceutical Technology

DECEMBER 25, 2023

BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

DECEMBER 24, 2023

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Colorectal Cancer.

Biopharma 40

Biopharma 40

Pharmaceutical Technology

DECEMBER 22, 2023

Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase III for Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

DECEMBER 26, 2023

FOG-001 is under clinical development by Fog Pharmaceuticals and currently in Phase II for Metastatic Colorectal Cancer.

Pharmaceutical 40

Pharmaceutical 40

World of DTC Marketing

DECEMBER 22, 2021

According to the American Society of Clinical Oncology Journal , “the remarkable frequency of delays and disruptions in health care mostly related to the reduction of the COVID-19 burden unintentionally posed a major risk on cancer care worldwide. Many patients are shunning hospitals and clinics.

Patients 241

Patients Doctors Healthcare Healthcare 241

Pharmaceutical Technology

DECEMBER 25, 2023

Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Metastatic Colorectal Cancer.

Biopharma 40

Biopharma 40

Pharmaceutical Technology

JUNE 5, 2023

Darovasertibis under clinical development by Ideaya Biosciences and currently in Phase II for Colorectal Cancer.

52

52

Pharmaceutical Technology

DECEMBER 21, 2023

Diakine-DK210 (EGFR) is under clinical development by Deka Biosciences and currently in Phase I for Colorectal Cancer.

40

40

Pharmaceutical Technology

DECEMBER 4, 2023

FPI-2059 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Metastatic Colorectal Cancer.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

DECEMBER 4, 2023

FPI-2059 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Metastatic Colorectal Cancer.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

DECEMBER 21, 2023

TAK-676 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Colorectal Cancer.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

DECEMBER 26, 2023

KSQ-4279 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Colorectal Cancer.

40

40

Pharmaceutical Technology

MAY 15, 2023

Innovent Biologics has secured breakthrough therapy designation (BTD) for IBI351 (GFH925) from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) to treat previously treated advanced colorectal carcinoma (CRC) patients with the KRAS G12C mutation.

Safety 52

Safety Patients Medical Marketing 52

Pharmaceutical Technology

DECEMBER 21, 2023

PF-07220060 is under clinical development by Pfizer and currently in Phase II for Colorectal Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Colorectal Cancer.

40

40

Pharmacy Times

JANUARY 18, 2023

The stool-test is the first-of-its-kind to detect CRC in adults aged 45 to 49 years, with a premarket approval submission planned to be sent to the FDA early in 2023.

FDA 48

FDA 48

Pharmaceutical Technology

OCTOBER 27, 2023

Ibrutinib is under clinical development by AbbVie and currently in Phase II for Colorectal Cancer.

40

40

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is developed based on DARPin technology.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

FEBRUARY 26, 2023

CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Biopharma 40

Biopharma Pharmaceutical 40

Pharmaceutical Technology

JUNE 30, 2023

XKDCT-080is under clinical development by Guangdong Xiankangda Biotechnology and currently in Phase II for Colorectal Cancer.

40

40

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-3082 is under clinical development by Astellas Pharma and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Pharma 40

Pharma Networking Pharmaceutical Manufacturing 40

Pharmaceutical Technology

FEBRUARY 24, 2023

Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Retail 40

Retail Distribution Pharmaceutical Pharmaceutical products 40

Pharmacy Times

JANUARY 6, 2023

The findings show promising clinical activity and a favorable tolerability profile in the treatment of KRASG12C-mutated advanced colorectal cancer.

FDA 49

FDA 49

Pharmaceutical Technology

FEBRUARY 23, 2023

Buparlisib hydrochloride is under clinical development by Adlai Nortye Biopharma and currently in Phase II for Mantle Cell Lymphoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Biopharma 52

Biopharma Pharmaceutical 52

Pharmaceutical Technology

APRIL 4, 2023

The collaboration will see the expansion of the investigative agent’s development, including activity in models of ovarian and other cancer types. Panbela claimed that ivospemin demonstrated signs of tumour growth inhibition in clinical trials involving patients with metastatic pancreatic cancer.

Medicine 59

Medicine FDA Leads Patients 59

Pharmaceutical Technology

APRIL 13, 2023

The therapy can deliver actinium-225 to solid tumours that express EGFR and cMET, both of which are validated targets co-expressed in many tumour types including non-small cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer and head and neck squamous cell carcinoma.

Food and Drug Administration 59

Food and Drug Administration Pharmaceutical FDA Food 59

Medgadget

SEPTEMBER 7, 2023

However, it is significantly more challenging to detect DNA inside the human body, although the clinical rewards could be huge – tumors can release DNA fragments into their surroundings, which float about. “The detection of gastrointestinal cancers and precancerous lesions is an attractive clinical opportunity to apply this invention.”

Engineering 107

Engineering 107

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Prescription 68

Prescription Pharmaceutical products Networking Manufacturing 68